seed
Stage
1
Investors
About
MoglingBio is developing pharmacological approaches to rejuvenate aged hematopoietic (blood-forming) stem cells by normalizing activity of the CDC42 protein, with the aim of restoring stem cell structure and function to improve blood and immune cell production and treat age-related blood and immune dysfunction.
Explore MoglingBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.